CIBC Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $202K | Hold |
725
| – | – | ﹤0.01% | 1227 |
|
|
2025
Q4 | $220K | Hold |
725
| – | – | ﹤0.01% | 1158 |
|
|
2025
Q3 | $203K | Buy |
+725
| New | +$197K | ﹤0.01% | 1155 |
|
|
2025
Q1 | – | Sell |
-713
| Closed | -$234K | – | 1188 |
|
|
2024
Q4 | $234K | Buy |
713
+34
| +5% | +$11.5K | ﹤0.01% | 1022 |
|
|
2024
Q3 | $227K | Sell |
679
-2,037
| -75% | -$647K | ﹤0.01% | 1023 |
|
|
2024
Q2 | $742K | Sell |
2,716
-231
| -8% | -$67.2K | ﹤0.01% | 688 |
|
|
2024
Q1 | $1.02M | Buy |
2,947
+77
| +3% | +$25.3K | ﹤0.01% | 675 |
|
|
2023
Q4 | $927K | Sell |
2,870
-99
| -3% | -$31K | ﹤0.01% | 666 |
|
|
2023
Q3 | $1.06M | Sell |
2,969
-60
| -2% | -$23.1K | ﹤0.01% | 638 |
|
|
2023
Q2 | $1.15M | Sell |
3,029
-34
| -1% | -$13.8K | ﹤0.01% | 641 |
|
|
2023
Q1 | $1.47M | Sell |
3,063
-53
| -2% | -$24.8K | 0.01% | 613 |
|
|
2022
Q4 | $1.31M | Sell |
3,116
-13
| -0.4% | -$5.25K | 0.01% | 629 |
|
|
2022
Q3 | $1.3M | Buy |
3,129
+172
| +6% | +$85.8K | 0.01% | 631 |
|
|
2022
Q2 | $1.46M | Sell |
2,957
-2,263
| -43% | -$1.18M | 0.01% | 589 |
|
|
2022
Q1 | $2.94M | Sell |
5,220
-1,103
| -17% | -$665K | 0.01% | 472 |
|
|
2021
Q4 | $4.78M | Buy |
6,323
+81
| +1% | +$60.6K | 0.02% | 379 |
|
|
2021
Q3 | $4.66M | Buy |
6,242
+250
| +4% | +$187K | 0.02% | 365 |
|
|
2021
Q2 | $3.86M | Buy |
5,992
+524
| +10% | +$319K | 0.02% | 396 |
|
|
2021
Q1 | $3.12M | Buy |
5,468
+336
| +7% | +$199K | 0.01% | 412 |
|
|
2020
Q4 | $2.99M | Buy |
5,132
+221
| +5% | +$126K | 0.01% | 396 |
|
|
2020
Q3 | $2.53M | Buy |
4,911
+2,780
| +130% | +$1.41M | 0.01% | 382 |
|
|
2020
Q2 | $962K | Buy |
2,131
+1,039
| +95% | +$459K | 0.01% | 572 |
|
|
2020
Q1 | $383K | Hold |
1,092
| – | – | ﹤0.01% | 676 |
|
|
2019
Q4 | $404K | Buy |
1,092
+11
| +1% | +$3.88K | ﹤0.01% | 776 |
|
|
2019
Q3 | $360K | Hold |
1,081
| – | – | ﹤0.01% | 773 |
|
|
2019
Q2 | $338K | Hold |
1,081
| – | – | ﹤0.01% | 812 |
|
|
2019
Q1 | $330K | Hold |
1,081
| – | – | ﹤0.01% | 810 |
|
|
2018
Q4 | $251K | Hold |
1,081
| – | – | ﹤0.01% | 841 |
|
|
2018
Q3 | $338K | Hold |
1,081
| – | – | ﹤0.01% | 810 |
|
|
2018
Q2 | $312K | Buy |
1,081
+35
| +3% | +$9.66K | ﹤0.01% | 818 |
|
|
2018
Q1 | $262K | Hold |
1,046
| – | – | ﹤0.01% | 851 |
|
|
2017
Q4 | $250K | Hold |
1,046
| – | – | ﹤0.01% | 891 |
|
|
2017
Q3 | $232K | Sell |
1,046
-8
| -0.8% | -$1.8K | ﹤0.01% | 904 |
|
|
2017
Q2 | $239K | Hold |
1,054
| – | – | ﹤0.01% | 851 |
|
|
2017
Q1 | $210K | Buy |
+1,054
| New | +$203K | ﹤0.01% | 900 |
|
Other funds holding BIO
VCM
VPM
AI
CIBC Asset Management's BIO Position: Q1 2026 in Review
CIBC Asset Management held its Bio-Rad Laboratories Class A (BIO) position steady in Q1 2026 at 725 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #1227.
CIBC Asset Management first reported a position in BIO in Q1 2017 and has held it in 35 quarters since. The position peaked at $4.78M in Q4 2021. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.
- CIBC Asset Management held 725 shares of Bio-Rad Laboratories Class A worth $202K as of Q1 2026.
- CIBC Asset Management left its Bio-Rad Laboratories Class A share count unchanged in Q1 2026.
- Bio-Rad Laboratories Class A made up ﹤0.01% of CIBC Asset Management's portfolio in Q1 2026, its #1227 holding.
- CIBC Asset Management first reported a position in Bio-Rad Laboratories Class A in Q1 2017 and has held it in 35 quarters since.
- CIBC Asset Management's Bio-Rad Laboratories Class A position peaked at $4.78M in Q4 2021.
- 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.
Based on CIBC Asset Management's 13F filing for Q1 2026, filed 12 May 2026.